Eli Lilly and Company $LLY Shares Bought by Cary Street Partners Financial LLC

Cary Street Partners Financial LLC grew its stake in Eli Lilly and Company (NYSE:LLY) by 12.0% during the third quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 28,051 shares of the company’s stock after purchasing an additional 2,999 shares during the quarter. Cary Street Partners Financial LLC’s holdings in Eli Lilly and Company were worth $21,403,000 as of its most recent filing with the SEC.

Other large investors have also modified their holdings of the company. Exencial Wealth Advisors LLC raised its holdings in shares of Eli Lilly and Company by 189.6% during the third quarter. Exencial Wealth Advisors LLC now owns 17,408 shares of the company’s stock valued at $13,283,000 after buying an additional 11,396 shares during the last quarter. Rede Wealth LLC acquired a new stake in Eli Lilly and Company in the 3rd quarter valued at approximately $487,000. Central Pacific Bank Trust Division increased its position in Eli Lilly and Company by 25.8% in the 3rd quarter. Central Pacific Bank Trust Division now owns 8,990 shares of the company’s stock valued at $6,859,000 after acquiring an additional 1,843 shares during the period. Cidel Asset Management Inc. raised its stake in Eli Lilly and Company by 26.5% during the 3rd quarter. Cidel Asset Management Inc. now owns 26,726 shares of the company’s stock valued at $20,392,000 after acquiring an additional 5,591 shares in the last quarter. Finally, Oak Family Advisors LLC acquired a new position in Eli Lilly and Company during the 3rd quarter worth $1,979,000. Institutional investors own 82.53% of the company’s stock.

Eli Lilly and Company Price Performance

Shares of NYSE:LLY opened at $1,042.68 on Wednesday. The company has a market capitalization of $983.62 billion, a PE ratio of 45.43, a price-to-earnings-growth ratio of 1.23 and a beta of 0.39. The company has a debt-to-equity ratio of 1.54, a quick ratio of 1.19 and a current ratio of 1.58. The stock has a fifty day moving average of $1,054.49 and a 200-day moving average of $923.72. Eli Lilly and Company has a one year low of $623.78 and a one year high of $1,133.95.

Eli Lilly and Company (NYSE:LLY) last issued its earnings results on Wednesday, February 4th. The company reported $7.54 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $7.48 by $0.06. Eli Lilly and Company had a return on equity of 102.94% and a net margin of 31.66%.The business had revenue of $19.29 billion for the quarter, compared to analysts’ expectations of $17.85 billion. During the same period in the previous year, the firm posted $5.32 EPS. The company’s quarterly revenue was up 42.6% on a year-over-year basis. Eli Lilly and Company has set its FY 2026 guidance at 33.500-35.000 EPS. As a group, equities analysts anticipate that Eli Lilly and Company will post 23.48 EPS for the current fiscal year.

Eli Lilly and Company Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 10th. Shareholders of record on Friday, February 13th will be paid a dividend of $1.73 per share. This is a boost from Eli Lilly and Company’s previous quarterly dividend of $1.50. This represents a $6.92 dividend on an annualized basis and a yield of 0.7%. The ex-dividend date of this dividend is Friday, February 13th. Eli Lilly and Company’s payout ratio is currently 30.15%.

Analyst Upgrades and Downgrades

A number of research analysts have recently commented on the company. The Goldman Sachs Group set a $1,260.00 price target on Eli Lilly and Company in a report on Thursday, February 5th. Wolfe Research increased their target price on shares of Eli Lilly and Company from $1,050.00 to $1,250.00 and gave the company an “outperform” rating in a research report on Wednesday, December 3rd. Leerink Partners raised their target price on shares of Eli Lilly and Company from $1,234.00 to $1,296.00 and gave the company an “outperform” rating in a research note on Thursday, February 5th. Sanford C. Bernstein reissued an “outperform” rating on shares of Eli Lilly and Company in a report on Friday, December 19th. Finally, Berenberg Bank lifted their price target on Eli Lilly and Company from $950.00 to $1,050.00 and gave the company a “hold” rating in a research report on Thursday, February 19th. Two research analysts have rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating and five have given a Hold rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $1,229.33.

Eli Lilly and Company News Summary

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Head‑to‑head trial news showing Novo’s next‑gen obesity candidate underperformed Lilly’s tirzepatide has strengthened expectations that Lilly will retain market share in the high-growth weight‑loss category; that data triggered earlier upside in LLY. Trial Readout Lifts Lilly
• Positive Sentiment: Lilly launched an FDA‑cleared multi‑dose KwikPen for Zepbound (tirzepatide), giving patients a more convenient monthly device at the same self‑pay price — a commercial move intended to improve adherence and retention. Zepbound KwikPen Launch
• Positive Sentiment: Wall Street remains constructive on LLY’s longer‑term outlook (Goldman and other analysts keep Buy/Outperform calls and elevated price targets), supporting the stock’s valuation against the sector noise. Analyst Support
• Neutral Sentiment: Early clinical work showing benefit of combining Zepbound with other therapies (e.g., Taltz) and investor commentary on retention strategies (multi‑dose pen) add incremental optionality but are not immediate revenue drivers. Pipeline/Combo Data
• Negative Sentiment: Nuevo pricing shock — Novo Nordisk announced U.S. list price cuts of up to ~50% for Ozempic/Wegovy (to ~$675/month starting 2027). That move has rattled the sector, and LLY shares have slipped as investors reassess pricing dynamics and potential margin/market‑share impacts across GLP‑1s. Novo Price Cut Hits Stocks
• Negative Sentiment: Broader competition and pricing pressure could compress realized prices or accelerate payer negotiations over time, a structural risk to growth if competitors follow price cuts or insurers demand steeper discounts. Price Competition Risk

About Eli Lilly and Company

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.